Gastric cancer or adenocarcinoma of the gastroesophageal junction
Conditions
Interventions
Observation group:None
Sponsors
Zhejiang Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age >= 18 years old, regardless of gender; 2.Diagnosed by organization and/or cytology as metastatic or locally advanced gastric cancer or gastroesophageal junction adenocarcinoma (Her-2 status is not limited, HER2 positive patients have previously received anti-HER2 treatment); 3.Have experienced at least one progression or failure of systemic therapy; 4.Starting from June 1, 2023, treatment with the combination of fruquintinib and irinotecan or albumin paclitaxel regimen, with at least one tumor assessment after treatment; 5.At least one measurable lesion (RECIST 1.1 standard); 6.ECOG physical condition 0-2 points; 7.Expected survival time >= 12 weeks; 8.Having sufficient organ and bone marrow function; 9.Good compliance and cooperation with follow-up;
Exclusion criteria
Exclusion criteria: 1.Suffering from other primary malignant tumors during the same period, excluding skin basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma in situ after radical surgery; 2.Simultaneously receiving other investigational drugs or approved anti-tumor treatments under development; 3.Drug therapy intervention for less than 2 treatment cycles; 4.Patients who cannot undergo efficacy evaluation and follow-up; 5.Researchers believe that patients who are not suitable for inclusion in this study;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-Free Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease Control Rate;Overall Survival;Objective Response Rate; | — |
Countries
China
Contacts
Public ContactXu Qi
Zhejiang Cancer Hospital
Outcome results
None listed